Publications

Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Rezūm System (Boston Scientific Corp.) for Benign Prostatic Hyperplasia

Focus of the Report: This report focuses on Rezūm water vapor therapy for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).

Technology Description: Rezūm is a minimally invasive surgical therapy that utilizes the convective principles …

Tavneos (Avacopan) for Anti-neutrophil Cytoplasmic Autoantibody-associated Vasculitis

Tavneos (avacopan) is an oral complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids.

Tivdak (Tisotumab Vedotin-tftv) for Cervical Cancer

Tivdak (tisotumab vedotin-tftv) is an intravenously administered tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.